Received: 24 September 2020
Accepted: 2 March 2021
First Online: 27 April 2021
: The project had ethics approval from the Victorian Cancer Biobank. The individual gave written consent. All patient information was de-identified. This study also received ethics approval from Deakin University Ethics Committee STEC-49-2014-ACKLAND.
: The patient gave written consent for their personal and clinical details to be published. There are no identifying images.
: MK reports consultant or advisory roles for AbbVie, Ipsen, Pfizer Roche, and Jackson Laboratory for Genomic Medicine; research funding from AbbVie, Bristol-Myers Squibb (BMS), and Specialized Therapeutics. The other authors declare no competing interests.